JP2023553210A5 - - Google Patents
Info
- Publication number
- JP2023553210A5 JP2023553210A5 JP2023559962A JP2023559962A JP2023553210A5 JP 2023553210 A5 JP2023553210 A5 JP 2023553210A5 JP 2023559962 A JP2023559962 A JP 2023559962A JP 2023559962 A JP2023559962 A JP 2023559962A JP 2023553210 A5 JP2023553210 A5 JP 2023553210A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- pharmaceutical composition
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN202011054571 | 2020-12-15 | ||
| IN202011054571 | 2020-12-15 | ||
| PCT/US2021/010067 WO2022132202A1 (en) | 2020-12-15 | 2021-12-15 | Combination therapy for the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023553210A JP2023553210A (ja) | 2023-12-20 |
| JP2023553210A5 true JP2023553210A5 (enExample) | 2024-12-24 |
Family
ID=82058750
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023559962A Pending JP2023553210A (ja) | 2020-12-15 | 2021-12-15 | がんの処置のための併用療法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240082394A1 (enExample) |
| EP (1) | EP4263584A4 (enExample) |
| JP (1) | JP2023553210A (enExample) |
| CN (1) | CN116940592A (enExample) |
| AU (1) | AU2021400979A1 (enExample) |
| CA (1) | CA3202374A1 (enExample) |
| WO (1) | WO2022132202A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202417012A (zh) * | 2022-08-19 | 2024-05-01 | 美商旗艦先鋒創新公司 | 包含myc調節劑及檢查點抑制劑之組合療法 |
| WO2024167880A1 (en) * | 2023-02-06 | 2024-08-15 | Bicara Therapeutics Inc. | Combination therapy and related methods |
| WO2024189544A1 (en) * | 2023-03-13 | 2024-09-19 | Janssen Biotech, Inc. | Combination therapies with bi-specific anti-egfr/c-met antibodies and anti-pd-1 antibodies |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5977316A (en) * | 1995-01-17 | 1999-11-02 | The Board Of Trustees Of The University Of Kentucky | Monoclonal antibody 1A7 and related polypeptides |
| CA3253628A1 (en) * | 2010-03-05 | 2025-11-29 | The Johns Hopkins University | Compositions and methods for targeted immunomodulatory antibodies and fusion proteins |
| PL3489254T3 (pl) * | 2012-04-30 | 2023-01-30 | Biocon Limited | Ukierunkowujące/immunomodulujące białko fuzyjne i sposoby jego otrzymywania |
| CA2902830C (en) * | 2013-03-12 | 2023-09-19 | Biocon Ltd. | Fusion immunomodulatory proteins and methods for making same |
| TWI681969B (zh) * | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| JP6695003B2 (ja) * | 2016-09-26 | 2020-05-20 | イムクローン・リミテッド・ライアビリティ・カンパニーＩｍｃｌｏｎｅ ＬＬＣ | 癌のための併用療法 |
| WO2019173692A2 (en) * | 2018-03-09 | 2019-09-12 | Agenus Inc. | Anti-cd73 antibodies and methods of use thereof |
-
2021
- 2021-12-15 AU AU2021400979A patent/AU2021400979A1/en active Pending
- 2021-12-15 WO PCT/US2021/010067 patent/WO2022132202A1/en not_active Ceased
- 2021-12-15 CA CA3202374A patent/CA3202374A1/en active Pending
- 2021-12-15 CN CN202180093680.4A patent/CN116940592A/zh active Pending
- 2021-12-15 EP EP21907338.4A patent/EP4263584A4/en active Pending
- 2021-12-15 US US18/256,761 patent/US20240082394A1/en active Pending
- 2021-12-15 JP JP2023559962A patent/JP2023553210A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106046155B (zh) | 用于治疗hbv感染及相关疾病的多肽及抗体 | |
| JP2023553210A5 (enExample) | ||
| JP2022546454A5 (enExample) | ||
| CN105829343A (zh) | Gitr抗原结合蛋白 | |
| JP2019534044A5 (enExample) | ||
| RU2009149294A (ru) | Антиген-связывающие белки, нацеленные на orf0657n s.aureus | |
| JP2023549537A5 (enExample) | ||
| RU2020113027A (ru) | Axl-специфичные антитела и их применения | |
| CA3001231C (en) | Antibody against hepatitis b surface antigen and use thereof | |
| JP2023544143A5 (enExample) | ||
| JP7455749B2 (ja) | 頭頸部癌の処置 | |
| EP2376119B1 (en) | Anti-hcv monoclonal antibody as a medicament for the therapeutic treatment and prevention of hcv infections | |
| WO2025246679A1 (zh) | 一种广谱中和冠状病毒的抗体及其应用 | |
| CN115160433A (zh) | 人源化hbv b和c基因型前s1蛋白抗体及其应用 | |
| JP2023534422A (ja) | Ｂ型肝炎ウイルスの表面抗原に結合する抗体及びその使用 | |
| JP2023500387A5 (enExample) | ||
| CN116178530A (zh) | 抗体在治疗SARS-CoV-2感染的用途 | |
| CN115957321A (zh) | 一种抗her2抗体在制备治疗癌症的药物中的用途 | |
| WO2023125289A1 (zh) | 抗pd-1抗体及其用途 | |
| CN115894691A (zh) | 靶向ror1的抗原结合蛋白 | |
| CN112175087A (zh) | 一种抗CD4和TGFβ的双特异性抗体、其药物组合及其用途 | |
| CN104861068B (zh) | 一种全人源抗her3抗体及其治疗相关疾病的用途 | |
| US20240018243A1 (en) | Antibody that specifically binds to human ctla4 and medicaments and kits comprising the same | |
| AU2020280543A1 (en) | Anti-hepatitis B virus antibodies and use thereof | |
| CN106963950B (zh) | 用于治疗肿瘤的联合用药物 |